




Attorney Docket No. 109336-132

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of: James McShane, et al.


Serial No.: 09/549,858

Filed: April 14, 2000

For: Pharmaceutical Formulation Comprising  
Glycine as a Stabilizer

Group Art Unit: 1614

Examiner: Not Yet Assigned



CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence and enclosures referenced herein are being deposited with the United States Postal Service as first class mail postage prepaid in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on October 13, 2000.

Sarah A. Marciano  
Sarah A. Marciano

Commissioner for Patents  
Washington, D.C. 20231

Sir:

**TRANSMITTAL LETTER**

Enclosed for filing in the United States Patent and Trademark Office are the following documents:

1. Request for Correction of the Official Filing Receipt;
2. Copy of original Filing Receipt with corrections;
3. Copy of Preliminary Amendment filed April 14, 2000;
4. Return postcard.

The Commissioner is authorized to charge any fees to our Deposit Account No. 08-0219. The Commissioner is further authorized to charge any fee or credit any overpayment to our Deposit Account No.08-0219.

Respectfully submitted,  
Hale and Dorr, LLP

Hollie L. Baker

Hollie L. Baker  
Reg. No. 31,321

October 13, 2000

Hale and Dorr LLP  
60 State Street  
Boston, MA 02109  
(617) 526-6110 (Telephone)  
(617) 526-5000 (Facsimile)



Attorney Docket No. 109536.132

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: James McShane, et al.

Serial No.: 09/549,858

Filed: April 14, 2000


For: Pharmaceutical Formulation Comprising  
Glycine as a Stabilizer

Group Art Unit: 1614

Examiner: Not Yet Assigned

**CERTIFICATE OF FIRST CLASS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on October 13, 2000.

  
Sarah Marciano

Attn: Customer Service Center  
Commissioner for Patents  
Washington, DC 20231

Sir:

**REQUEST FOR CORRECTION OF THE OFFICIAL FILING RECEIPT**

Applicants notify the U.S. Patent and Trademark Office of the errors on the Official Filing Receipt and hereby request correction. A copy of the Official Filing Receipt is attached, with the errors noted and corrected. The corrections should be as follows:

The inventor's name should be corrected as follows:

**Katsumi Onai.**

The title of the invention should be corrected as follows:

**Pharmaceutical Formulation Comprising Glycine as a Stabilizer.**


A copy of the Preliminary Amendment filed on April 14, 2000 showing the amended title is enclosed.

**RECEIVED**  
JAN 19 2001  
TECH CENTER 1600/2600

The Commissioner is authorized to debit any fee or credit any overpayment to our  
Deposit Account No. 08-0219.

Respectfully submitted,

October 13, 2000

  
\_\_\_\_\_  
Hollie L. Baker  
Reg. No. 31,321

HALE AND DORR LLP  
60 State Street  
Boston, MA 02109  
Tel. (617) 526-6110  
Fax. (617) 526-5000

sarah marcano - h:\baker\_hollie\legal\eisai\109536.132\documents\corrfilec.doc

JCT



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART. NO.	FILED REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/549,858	04/14/2000	1614	874	0882/1D235- US1	5	23	2

Darby & Darby  
805 Third Avenue  
New York, NY 10022

OCT 10 2000  
DOCKET  
DEPT.  
INTELLECTUAL PROPERTY  
DEPARTMENT

## FILING RECEIPT



\*OC00000005369024\*

Date Mailed: 08/31/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

James McShane, Wake Forest, NC ;  
Ray Wood, Raleigh, NC ;  
Sumio Watanabe, Fuso-cho, JAPAN;  
Kiyoshi Iwamoto, Kagamihara-shi, JAPAN;  
Katsumi Onal, Aichi, JAPAN; **KATSUMI ONAI**

## Continuing Data as Claimed by Applicant

## Foreign Applications

UNITED STATES OF AMERICA 60062089 10/14/1997

If Required, Foreign Filing License Granted 06/23/2000

## Title

Pharmaceutical Formulation Comprising Glycine as a  
Stabilizer  
Pharmaceutical formulation and method of preparation

## Preliminary Class

514

DOCKETED LD 1000000

Data entry by : BATIE, MARGARET

Team: OIPE

Date: 08/31/2000



**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231

